Measuring bFGF Levels in Tumors to Understand Chemoresistance
Author Information
Author(s): Colin T Walsh, Yong Wei, M Guillaume Wientjes, Jessie LS Au
Primary Institution: The Ohio State University
Hypothesis
The study aims to quantify bFGF levels in archived tumor tissues and determine its relationship with chemosensitivity.
Conclusion
The study established a method to measure bFGF levels in tumors, revealing a significant correlation between bFGF levels and tumor sensitivity to paclitaxel.
Supporting Evidence
- The study found a significant correlation between bFGF levels and tumor sensitivity to paclitaxel.
- Image analysis provided more robust data compared to conventional visual scoring methods.
- Higher correlations were observed in specific tumor subgroups with different pathobiological properties.
Takeaway
Researchers found a way to measure a protein in tumors that helps understand how well cancer responds to a drug called paclitaxel.
Methodology
The study used image analysis to quantify bFGF levels in tumor tissues and evaluated their relationship with paclitaxel sensitivity using linear regression.
Potential Biases
The visual examination method may introduce unintended bias due to subjective scoring.
Limitations
The study is limited by the retrospective nature of using archived tissues and potential biases in visual scoring methods.
Participant Demographics
The study included 87 patient tumors from various types including bladder, breast, head and neck, ovarian, and prostate cancers.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI around r2: 0.074–0.370
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website